Literature DB >> 31127020

Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.

Jih-Hsiang Lee1,2,3, Hsuan-Yu Chen4, Feng-Ming Hsu1, Jin-Shing Chen5, Wei-Yu Liao6, Jin-Yuan Shih6, Chong-Jen Yu6, Kuan-Yu Chen6, Tzu-Hsiu Tsai6, James Chih-Hsin Yang7,2.   

Abstract

BACKGROUND: Immediate whole brain radiation (WBRT) has been the standard for patients with lung cancer with brain metastases. The study aims to evaluate the effect of immediate cranial irradiation in patients with epidermal growth factor receptor (EGFR) mutant lung cancer in the era of a new generation of EGFR inhibitors.
MATERIALS AND METHODS: Medical records of 198 patients with EGFR mutant non-small cell lung cancer and brain metastases at initial metastatic diagnosis were reviewed. Patients were categorized into four groups: immediate WBRT, immediate cranial stereotactic radiosurgery (SRS), delayed radiation upon progression of cranial lesions (DRT), and never cranial irradiation (NRT). Overall survival (OS) and progression-free survival related to EGFR inhibitors were analyzed.
RESULTS: The SRS group had the fewest brain metastases and fewest extracranial lesions, and the DRT and NRT groups had the smallest brain metastases. Median survival were 18.5, 55.7, 21.1, and 18.2 months for the WBRT, SRS, DRT, and NRT groups, respectively. Patients who had received EGFR T790M inhibitors survived longer (41.1 vs. 19.8 months). In multivariate analysis, the OS of patients in the SRS group was longer than that in the NRT group (adjusted hazard ratio [aHR]: 0.315). Patients who had fewer extracranial lesions and who had received EGFR T790M inhibitor treatments also survived longer (aHR: 0.442 and 0.357, respectively).
CONCLUSION: Immediate stereotactic radiosurgery but not whole brain radiation was associated with longer survival. Because of patient heterogeneity and the introduction of EGFR T790M inhibitors, the timing and modality of cranial irradiation should be determined individually, and cranial irradiation may be omitted for selected patients. IMPLICATIONS FOR PRACTICE: Immediate whole brain radiation has been the standard for patients with lung cancer with brain metastases. In this study, it was observed that, for patients with epidermal growth factor receptor (EGFR) mutant advanced lung cancer who had brain metastases, there was no difference in survival between patients who never received cranial irradiation and those who received whole brain radiation immediately. Patients who received immediate stereotactic radiosurgery or who had ever received EGFR T790M inhibitors survived longer. Patients who received immediate stereotactic radiosurgery have fewer brain metastases. These findings suggest that the timing and modality of cranial irradiation should be determined individually, and cranial irradiation may be omitted in selected patients. © AlphaMed Press 2019.

Entities:  

Keywords:  Brain metastases; Cranial irradiation; Epidermal growth factor receptor; Non‐small cell lung cancer; Targeted therapies

Year:  2019        PMID: 31127020      PMCID: PMC6975931          DOI: 10.1634/theoncologist.2019-0152

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  24 in total

Review 1.  Brain metastases in non-small-cell lung cancer.

Authors:  David E Dawe; Jeffrey N Greenspoon; Peter M Ellis
Journal:  Clin Lung Cancer       Date:  2014-05-13       Impact factor: 4.785

2.  EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases.

Authors:  Tao Jiang; Chunxia Su; Xuefei Li; Chao Zhao; Fei Zhou; Shengxiang Ren; Caicun Zhou; Jun Zhang
Journal:  J Thorac Oncol       Date:  2016-05-26       Impact factor: 15.609

3.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Thanyanan Reungwetwattana; Kazuhiko Nakagawa; Byoung Chul Cho; Manuel Cobo; Eun Kyung Cho; Alessandro Bertolini; Sabine Bohnet; Caicun Zhou; Ki Hyeong Lee; Naoyuki Nogami; Isamu Okamoto; Natasha Leighl; Rachel Hodge; Astrid McKeown; Andrew P Brown; Yuri Rukazenkov; Suresh S Ramalingam; Johan Vansteenkiste
Journal:  J Clin Oncol       Date:  2018-08-28       Impact factor: 44.544

Review 4.  Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

Authors:  Chee Khoon Lee; Chris Brown; Richard J Gralla; Vera Hirsh; Sumitra Thongprasert; Chun-Ming Tsai; Eng Huat Tan; James Chung-Man Ho; Da Tong Chu; Adel Zaatar; Jemela Anne Osorio Sanchez; Vu Van Vu; Joseph Siu Kie Au; Akira Inoue; Siow Ming Lee; Val Gebski; James Chih-Hsin Yang
Journal:  J Natl Cancer Inst       Date:  2013-04-17       Impact factor: 13.506

5.  Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

Authors:  Myung-Ju Ahn; Dong-Wan Kim; Byoung Chul Cho; Sang-We Kim; Jong Seok Lee; Jin-Seok Ahn; Tae Min Kim; Chia-Chi Lin; Hye Ryun Kim; Thomas John; Steven Kao; Jonathan W Goldman; Wu-Chou Su; Ronald Natale; Sarit Rabbie; Bryony Harrop; Philip Overend; Zhenfan Yang; James Chih-Hsin Yang
Journal:  Lancet Respir Med       Date:  2017-10-19       Impact factor: 30.700

6.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).

Authors:  Paul W Sperduto; T Jonathan Yang; Kathryn Beal; Hubert Pan; Paul D Brown; Ananta Bangdiwala; Ryan Shanley; Norman Yeh; Laurie E Gaspar; Steve Braunstein; Penny Sneed; John Boyle; John P Kirkpatrick; Kimberley S Mak; Helen A Shih; Alex Engelman; David Roberge; Nils D Arvold; Brian Alexander; Mark M Awad; Joseph Contessa; Veronica Chiang; John Hardie; Daniel Ma; Emil Lou; William Sperduto; Minesh P Mehta
Journal:  JAMA Oncol       Date:  2017-06-01       Impact factor: 31.777

7.  Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.

Authors:  Peter Ballard; James W T Yates; Zhenfan Yang; Dong-Wan Kim; James Chih-Hsin Yang; Mireille Cantarini; Kathryn Pickup; Angela Jordan; Mike Hickey; Matthew Grist; Matthew Box; Peter Johnström; Katarina Varnäs; Jonas Malmquist; Kenneth S Thress; Pasi A Jänne; Darren Cross
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

8.  Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC).

Authors:  Qianqian Zhu; Yanan Sun; Yingying Cui; Ke Ye; Chengliang Yang; Daoke Yang; Jie Ma; Xiao Liu; Jinming Yu; Hong Ge
Journal:  Oncotarget       Date:  2017-02-21

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.

Authors:  Chia-Chi Lin; Jin-Yuan Shih; Chong-Jen Yu; Chao-Chi Ho; Wei-Yu Liao; Jih-Hsing Lee; Tzu-Hsiu Tsai; Kang-Yi Su; Min-Shu Hsieh; Yih-Leong Chang; Ya-Ying Bai; Derek De-Rui Huang; Kenneth S Thress; James Chih-Hsin Yang
Journal:  Lancet Respir Med       Date:  2017-12-14       Impact factor: 30.700

View more
  9 in total

Review 1.  The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

Authors:  Alessia Spagnuolo; Matteo Muto; Fabio Monaco; Giuseppe Colantuoni; Cesare Gridelli
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  Focal Radiotherapy of Brain Metastases in Combination With Immunotherapy and Targeted Drug Therapy.

Authors:  David Kaul; Anna Sophie Berghoff; Anca-Ligia Grosu; Carolin Weiss Lucas; Matthias Guckenberger
Journal:  Dtsch Arztebl Int       Date:  2021-11-12       Impact factor: 5.594

3.  EGFR mutant status and tyrosine-kinase inhibitors affect the GKRS outcomes for NSCLC brain metastases.

Authors:  Hung-Ruei Liao; Chi-Lu Chiang; Chia-I Shen; Ching-Jen Chen; Huai-Che Yang; Hsiu-Mei Wu; Yung-Hung Luo; Yong-Sin Hu; Chung-Jung Lin; Wen-Yuh Chung; Cheng-Ying Shiau; Wan-Yuo Guo; David Hung-Chi Pan; Cheng-Chia Lee
Journal:  J Neurooncol       Date:  2022-08-17       Impact factor: 4.506

Review 4.  A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player.

Authors:  Yue Zhou; Fan Yu; Yang Zhao; Ya Zeng; Xi Yang; Li Chu; Xiao Chu; Yida Li; Liqing Zou; Tiantian Guo; Zhengfei Zhu; Jianjiao Ni
Journal:  Transl Lung Cancer Res       Date:  2020-12

5.  Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.

Authors:  Ya Zeng; Tiantian Guo; Yue Zhou; Yang Zhao; Li Chu; Xiao Chu; Xi Yang; Jianjiao Ni; Zhengfei Zhu
Journal:  BMC Cancer       Date:  2022-02-21       Impact factor: 4.430

6.  Effect of brain radiotherapy strategies on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis.

Authors:  Guangchuan Deng; Yingyun Zhang; Jiaojiao Ke; Qi Wang; Hongyue Qin; Jianbin Li; Zhenxiang Li
Journal:  J Transl Med       Date:  2021-11-30       Impact factor: 5.531

Review 7.  International consensus on radiotherapy in metastatic non-small cell lung cancer.

Authors:  Zhengfei Zhu; Jianjiao Ni; Xuwei Cai; Shengfa Su; Hongqing Zhuang; Zhenzhou Yang; Ming Chen; Shenglin Ma; Conghua Xie; Yaping Xu; Jiancheng Li; Hong Ge; Anwen Liu; Lujun Zhao; Chuangzhou Rao; Congying Xie; Nan Bi; Zhouguang Hui; Guangying Zhu; Zhiyong Yuan; Jun Wang; Lina Zhao; Wei Zhou; Chai Hong Rim; Arturo Navarro-Martin; Ben G L Vanneste; Dirk De Ruysscher; J Isabelle Choi; Jacek Jassem; Joe Y Chang; Lucyna Kepka; Lukas Käsmann; Michael T Milano; Paul Van Houtte; Rafal Suwinski; Alberto Traverso; Hiroshi Doi; Yang-Gun Suh; Georges Noël; Natsuo Tomita; Roman O Kowalchuk; Terence T Sio; Baosheng Li; Bing Lu; Xiaolong Fu
Journal:  Transl Lung Cancer Res       Date:  2022-09

8.  The value of local consolidative therapy in Osimertinib-treated non-small cell lung cancer with oligo-residual disease.

Authors:  Ya Zeng; Jianjiao Ni; Fan Yu; Yue Zhou; Yang Zhao; Shuyan Li; Tiantian Guo; Li Chu; Xi Yang; Xiao Chu; Xuwei Cai; Zhengfei Zhu
Journal:  Radiat Oncol       Date:  2020-08-27       Impact factor: 3.481

Review 9.  EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?

Authors:  Bailong Liu; Hui Liu; Yunfei Ma; Qiuhui Ding; Min Zhang; Xinliang Liu; Min Liu
Journal:  Cancer Med       Date:  2021-08-10       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.